ArticleJournal of virology2014
Immunogenicity studies of proteins forming the T4 phage head surface.
Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 173 citations in OpenAlex.
- Antibodies targeting phage fiber and nozzle proteins impair Acinetobacter baumannii phage therapy by blocking infection and promoting immune clearance.PLoS biology · 2026Article
- Strong mucosal adhesion enhances the anti-infective effectiveness of T4-like phages.Applied and environmental microbiology · 2026Article
- Article
- Immune Responses to Phage Therapy in Humans: A Review.The Journal of infectious diseases · 2026Review
- Immune Protection Effect of an OmpC-Recombinant T4 Bacteriophage Vaccine Against Infection Caused by Extraintestinal PathogenicVaccines · 2026Article
- Assessing the impact of phage therapy on growth performance, microbiome and phage specific immune response in chickens.Scientific reports · 2026Article
- Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics.Chemical science · 2026Review
- Bacteriophage Therapy: Overcoming Antimicrobial Resistance Through Advanced Delivery Methods.Molecules (Basel, Switzerland) · 2026Review
- Structural Remodeling of Phage φPNJ-6 Hoc Promotes Adhesion to the Intestinal Epithelium.Transboundary and emerging diseases · 2026Article
- Harnessing phages in the age of antibiotic resistance: immunological perspectives.Frontiers in immunology · 2026Review
- Detectable effects of bacterial phylogeny on virulence but not phage efficacy in anISME communications · 2026Article
- Analysis of Pro- and Anti-Inflammatory Gene Response Patterns in Patients Receiving Phage Therapy.International journal of molecular sciences · 2025Observational
- Article
- Intranasal phage therapy overcomes antibody neutralization challenges in pulmonary Pseudomonas aeruginosa infections.Archives of microbiology · 2025Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- Phage-Microbiota Crosstalk: Implications for Central Nervous System Disorders.International journal of molecular sciences · 2025Review
- Large-Scale Genomic Analysis of CpG-Mediated Immunogenicity in Bacteriophages and a Novel Predictive Risk Index.bioRxiv : the preprint server for biology · 2025Article
- Differences in Phage Recognition and Immunogenicity Contribute to Divergent Human Immune Responses to Escherichia coli and Klebsiella pneumoniae Phages.European journal of immunology · 2025Article
- Assembly and performance of a cholera RDT prototype that detects bothJournal of clinical microbiology · 2025Article
- Transcytosis of T4 Bacteriophage Through Intestinal Cells Enhances Its Immune Activation.Viruses · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledAdvances in phage therapy and novel applications of phages in biotechnology encourage interest in phage impact on human and animal immunity. Here we present comparative studies of immunogenic properties of T4 phage head surface proteins gp23*, gp24*, Hoc, and Soc, both as elements of the phage capsid and as isolated agents. Studies comprise evaluation of specific antibodies in the human population, analysis of the proteins' impact on the primary and secondary responses in mice, and the effect of specific antibodies on phage antibacterial activity in vitro and in vivo in mice. In humans, natural antibodies specific to T4-like phages were abundant (81% of investigated sera). Among those, significantly elevated levels of IgG antibodies only against major head protein (gp23*) were found, which probably reflected cross-reactions of T4 with antibodies induced by other T4-like phages. Both IgM and IgG antibodies were induced mostly by gp23* and Hoc, while weak (gp24*) and very weak (Soc) reactivities of other head proteins were noticed. Thus, T4 head proteins that markedly contribute to immunological memory to the phage are highly antigenic outer capsid protein (Hoc) and major capsid protein (gp23*). Specific anti-gp23* and anti-Hoc antibodies substantially decreased T4 phage activity in vitro and to some extent in vivo. Cooperating with antibodies, the immune complement system also contributed to annihilating phages. IMPORTANCE: Current descriptions of phage immunogenicity and its biological consequences are still vague and incomplete; thus, the central problem of this work is timely and may have strong practical implications. Here is presented the very first description of the contribution of bacteriophage proteins to immunological memory of the phage. Understanding of interactions between phages and mammalian immunology may help in biotechnological adaptations of phages for therapeutic requirements as well as for better appreciation of phage ecology and their role in the biosphere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.